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ABSTRACT
Pediatric high-grade glioma (HGG, WHO Grade III and IV) is a devastating 
brain tumor with a median survival of less than two years. PDGFRA is frequently 
mutated/ amplified in pediatric HGG, but the significance of this finding has not been 
fully characterized. We hypothesize that alterations of PDGFRA will promote distinct 
prognostic and treatment implications in pediatric HGG. In order to characterize the 
impact of PDGFR pathway alterations, we integrated genomic data from pediatric 
HGG patients (n=290) from multiple pediatric datasets and sequencing platforms. 
Integration of multiple human datasets showed that PDGFRA mutation, but not 
amplification, was associated with older age in pediatric HGG (P= <0.0001). In 
multivariate analysis, PDGFRA mutation was correlated with worse prognosis 
(P = 0.026), while PDGFRA amplification was not (P = 0.11). By Kaplan-Meier analysis, 
non-brainstem HGG with PDGFRA amplification carried a worse prognosis than non-
brainstem HGG without PDGFRA amplification (P = 0.021). There were no pediatric 
patients with PDGFRA-amplified HGG that survived longer than two years. Additionally, 
we performed paired molecular profiling (germline / tumor / primary cell culture) 
and targeting of an infant thalamic HGG with amplification and outlier increased 
expression of PDGFRA. Dasatinib inhibited proliferation most effectively. In summary, 
integration of the largest genomic dataset of pediatric HGG to date, allowed us to 
highlight that PDGFRA mutation is found in older pediatric patients and that PDGFRA 
amplification is prognostic in non-brainstem HGG. Future precision-medicine based 
clinical trials for pediatric patients with PDGFRA-altered HGG should consider the 
optimized delivery of dasatinib.
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INTRODUCTION
Pediatric high-grade glioma (WHO Grade III 
and IV) is a devastating brain tumor carrying a poor 
prognosis. Despite histologic similarities to adult high-
grade glioma (HGG), there are important differences 
from tumors arising in younger patients. In particular, 
pediatric HGG arises in different locations, more often 
in midline structures such as the brainstem and thalamus. 
As well, pediatric high grade gliomas almost always 
develop de novo as high-grade lesions, as opposed to 
secondary GBM seen in some adult patients [1-3]. For 
older children with HGG, treatment is similar to adult 
patients, with attempt at maximal resection, followed by 
treatment with focal radiation, often with the addition of 
temozolomide. Infants are often treated with intensive 
multi-agent chemo with the goal of avoiding or delaying 
radiation [4]. These treatments are rarely curative, and 
70-90% of patients with pediatric HGG will die within 
two years of diagnosis [2].
Recent molecular profiling of pediatric HGG 
has further highlighted important biologic differences 
with adult HGG. Recurrent mutations in the histone 
gene H3F3A are seen almost exclusively in pediatric 
HGG, and mutations in TP53 and the histone 
chaperone protein ATRX are seen more frequently in 
pediatric HGG [5, 6]. These histone mutations lead 
to epigenetic changes resulting in transcriptional 
changes of developmental genes, and highlight the 
unique pressures that may drive tumor growth in the 
developing brain [1]. In fact, molecular characterization 
of pediatric HGGs has documented key differences 
among different sub-populations of pediatric patients, 
as separated by age and location [1]. As well, treatment 
responses may be different, with infants possibly 
representing a more chemotherapy-responsive sub-
group [1]. These distinctions highlight the importance 
of future treatments in HGG being tailored to the 
molecular attributes of the individual tumor of the 
patient.
Recent work has also documented the mutation, 
amplification and up-regulation of PDGFRA in a 
significant subset (15-39%) of pediatric patients with 
HGG [2, 3]. PDGFRA is amplified less frequently 
in adult HGG, but has been found to carry a worse 
prognosis in adult anaplastic astrocytoma (WHO grade 
III glioma) [7]. An analysis of adult and pediatric HGGs 
showed that PDGFRA amplification by FISH carried a 
worse prognosis in adult IDH1-mutated HGG, but not 
in pediatric HGG [8]. Previous large scale genomic 
studies of pediatric HGG [2, 3] have not focused on the 
unique prognostic and treatment implication of PDGFRA 
alterations. In order to fully characterize the impact of 
PDGFRA alterations in pediatric HGG patients, we 
integrated genomic data from multiple datasets and 
sequencing platforms to create a large pediatric HGG 
genomic dataset (n=290).
In order to further explore the ability to target 
PDGFRA-amplified pediatric HGG, we generated a 
novel pediatric HGG primary cell culture with confirmed 
PDGFRA amplification. We performed molecular 
characterization of the matched tumor and the primary 
cell culture, and describe the successful targeting of 
PDGFRA with clinically available receptor tyrosine kinase 
inhibitors. Our genomic analysis and in vitro data provide 
compelling evidence for the continued optimization 
of dasatinib delivery for pediatric HGG patients with 
confirmed PDGFRA alteration.
RESULTS
To assess the impact of PDGFRA alterations 
on survival in pediatric HGG patients, we retrieved 
multiple datasets of publicly available genome-wide 
data available in the European Genome Archive (EGA). 
We then integrated multiple sequencing platforms used 
for these datasets to produce full somatic sequence and 
copy number information on 290 pediatric high-grade 
glioma (HGG) samples (up to age 30), including 137 
diffuse intrinsic pontine glioma (DIPG) and 153 non-
brainstem HGG (22 anaplastic astrocytomas (WHO grade 
III), 125 glioblastomas (WHO grade IV), 1 anaplastic 
ganglioglioma, 1 gliomatosis cerebri, and 4 high-grade 
glioma, not otherwise specified). Of these samples, 26 
(8.9%) carried PDGFRA mutations, 22 (7.5%) carried 
PDGFRA amplifications, 6 (2.0%) carried both PDGFRA 
mutation and amplification, for a total of 41 samples 
with PDGFRA alterations (14.1%) (Table 1). PDGFRA 
amplification was not associated with TP53, FGFR1, 
ATRX and IDH1 mutations by McNemar’s test (P < 
0.05 and kappa < 0.07 for all comparisons)). PDGFRA 
mutation was not associated with TP53, FGFR1, and 
IDH1 mutations (P < 0.001 and kappa < 0.12 for all 
comparisons). There appeared to be a slight association 
between PDGFRA mutation and ATRX mutation (P=0.11 
and kappa=0.17).
PDGFRA mutation, but not amplification, was 
associated with older age in pediatric HGG (average age 
14.5 years (mutated) and 9.4 years (non-mutated); P = 
< 0.0001) (Figure 1A). PDGFRA alterations combined 
(mutation and/or amplification) were also seen in older 
patients (13.1 years) compared to PDGFRA wild-
type pediatric HGG (9.3 years; P = 0.003). PDGFRA 
amplification was more frequently found in the brainstem; 
compared to PDGFRA mutation, which was more 
frequently hemispheric (Figure 1B).
PDGFRA amplification was associated with worse 
overall survival, when compared by Kaplan-Meier 
analysis (Figure 2A, P = 0.0058). PDGFRA mutation, 
on the other hand, was not associated with a survival 
Oncotarget3www.impactjournals.com/oncotarget
Table 1: Characteristics of pediatric HGGs with PDGFRA alterations 
sample ID sex PDGFRA 
mutation
PDGFRA 
mutation type
PDGFRA 
copy number
age diagnosis location OS  
(if known)
status  
(if known)
PDGFRA 
mutation and 
amplification
pHGG_ 194 F N468S Missense AMP 12.9 AA Hemispheric 4.6 DOD
pHGG_266 M Y288C Missense AMP 22.7 AA Hemispheric 18.0 DOD
pHGG_126 F N659K Missense AMP 7.6 DIPG Brainstem 12.7 DOD
pHGG_127 M T281P Missense AMP 7.8 DIPG Brainstem 4.4 DOD
pHGG_226 M I843fs IF del AMP 14.8 GBM Hemispheric 13.0 DOD
pHGG_138 F A341T Missense AMP 8.7 GBM Midline
PDGFRA 
mutation 
alone
pHGG_64 F 543fs IF ins NC 5.3 DIPG Brainstem 8.7 DOD
pHGG_66 F A529fs IF ins NC 5.3 DIPG Brainstem
pHGG_175 F A341T Missense NC 11.0 DIPG Brainstem
pHGG_191 F N659K Missense NC 12.5 DIPG Brainstem 9.6 DOD
pHGG_58 M K385I Missense NC 5.0 GBM Hemispheric 6.0 DOD
pHGG_102 M Y288C Missense NC 6.5 GBM Hemispheric 9.9 DOD
pHGG_168 F 384fs FS NC 10.9 GBM Hemispheric
pHGG_224 F E311fs FS NC 14.4 GBM Hemispheric 16.5 DOD
pHGG_238 F D583fs IF del NC 15.8 GBM Hemispheric 12.9 DOD
pHGG_243 M R491fs IF ins NC 16.7 GBM Hemispheric 9.2 DOD
pHGG_254 F C235Y Missense NC 19.0 GBM Hemispheric 21.0 DOD
pHGG_259 F K385M Missense NC 20.0 GBM Hemispheric
pHGG_262 F V561A Missense NC 21.0 GBM Hemispheric 25.0 alive
pHGG_268 F Y288C Missense NC 24.0 GBM Hemispheric
pHGG_269 M D576G Missense NC 25.0 GBM Hemispheric 0.1 DOD
pHGG_272 M C235Y Missense NC 27.0 GBM Hemispheric 15.0 DOD
pHGG_277 M V336fs IF del NC 30.0 GBM Hemispheric 27.0 alive
pHGG_51 M N659K Missense NC 4.7 GBM Midline 6.7 DOD
pHGG_183 F D842fs NonFS indel NC 12.0 GBM Midline 8.0 DOD
pHGG_248 M Y555C Missense NC 17.2 GBM Midline 11.5 DOD
PDGFRA 
amplification 
alone
pHGG_12 M AMP 1.8 DIPG Brainstem 20.9 DOD
pHGG_46 F AMP 4.5 DIPG Brainstem
pHGG_95 M AMP 6.1 DIPG Brainstem 14.4 DOD
pHGG_99 F AMP 6.4 DIPG Brainstem 5.5 DOD
pHGG_112 M AMP 7.0 DIPG Brainstem
pHGG_119 M AMP 7.2 DIPG Brainstem 6.0 DOD
pHGG_125 M AMP 7.6 DIPG Brainstem 2.8 DOD
pHGG_158 F AMP 10.0 DIPG Brainstem 10.0 DOD
pHGG_165 M AMP 10.6 DIPG Brainstem 10.2 DOD
pHGG_227 F AMP 15.0 DIPG Brainstem 13.4 DOD
pHGG_236 M AMP 15.6 DIPG Brainstem 1.2 DOD
pHGG_178 M AMP 11.5 GBM Hemispheric 5.0 alive
(Continued )
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difference (Figure 2B, P=0.26). When separated by 
anatomical location and Kaplan-Meier analysis, PDGFRA 
amplification remained associated with worse prognosis 
in non-brainstem HGG (Figure 2C, P=0.026), but not 
brainstem HGG (DIPG) (Figure 2D, P=0.26). However, 
when using a multivariate analysis and adjusting for age 
and location, PDGFRA mutation was correlated with 
worse prognosis (P = 0.026), while PDGFRA amplification 
was not (P = 0.11).
In order to further explore the biology of PDGFRA-
amplified pediatric HGG, we performed molecular 
characterization and primary cell culture generation 
of pediatric patients presenting to the University of 
Michigan with HGG. A two-year old patient presented to 
sample ID sex PDGFRA 
mutation
PDGFRA 
mutation type
PDGFRA 
copy number
age diagnosis location OS  
(if known)
status  
(if known)
pHGG_242 F AMP 16.6 GBM Hemispheric 12.0 DOD
pHGG_252 M AMP 17.8 GBM Hemispheric 8.9 DOD
pHGG_265 M AMP 22.7 GBM Hemispheric 11.9 DOD
IF del = in-frame deletion; FS = frameshift; IF ins = in-frame insertion; NonFS indel = non frameshift insertion/deletion; 
AMP = amplified; NC = normal copy number; AA = anaplastic astrocytoma; DIPG = diffuse intrinsic pontine glioma; 
GBM = glioblastoma; OS = overall survival; DOD = died of disease.
Figure 1: PDGFRA mutation is seen in older pediatric HGG patients. A. Individual data points represent individual patients 
in pediatric HGG dataset (n=290), with lines representing mean and standard error of measurement (SEM). PDGFRA mutation (purple) 
was associated with older age in pediatric HGG compared to non-mutated PDGFRA (blue). Comparison was made using an unpaired t-test 
(**** = P<0.0001; *** = P<0.001, NS = P>0.05). B. Location of PDGFRA mutation (purple circles) and PDGFRA amplification (red 
circles) is represented by circle size that is proportional to frequency in pediatric HGG patients. **** = P<0.0001; *** = P<0.001; NS = 
P>0.05; AA = anaplastic astrocytoma; GBM = glioblastoma.
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the University of Michigan with a new infiltrative intra-
cranial mass centered in the region of the left thalamus 
with extension into the left basal ganglia (Figure 3A). The 
tumor was partially resected and revealed a hypercellular 
spindle neoplasm, with prominent mitotic activity, without 
definite microvascular proliferation or necrosis. The 
tumor was strongly immuno-reactive for GFAP (Figure 
3B), SMARCB/INI-1 was preserved, and the tumor was 
negative for chromogranin, synaptophysin, Cam 5.2, 
EMA, desmin, myogenin, neurofilament and mutant-
specific IDH1 (R132H). Proliferation index (Ki-67) 
was markedly elevated (about 60%) (Figure 3B). These 
histologic findings (and the molecular profiling below) 
were consistent with a high-grade glioma (grade III/IV); 
but lack of microvascular proliferation or necrosis in 
examined tissue did not allow us to differentiate between 
WHO grade III or IV glioma.
Integrative clinical sequencing revealed somatic 
tumor gene amplifications and outlier increased expression 
of PDGFRA, MYC, PVT1, CHIC2, RBPJ, FGF2, ING4, 
and ZNF384 (Figure 4A–4B and full sequencing details in 
Supplementary Figure S1). The tumor showed no H3F3A 
or TP53 mutations, which are frequently seen in this 
patient population [3].
In order to generate the primary tumor cell culture 
(UMPED05), fresh tumor tissue was collected at the 
time of resection, non-enzymatically dissociated, filtered 
and maintained in serum-containing media without any 
additional growth factor supplementation. The tumor 
cells grew adherently in vitro. We performed molecular 
Figure 2: PDGFRA amplification is associated with worse prognosis in pediatric HGG. A. Kaplan-Meier analysis of overall 
survival of 290 pediatric high-grade glioma patients from multiple integrated sequencing datasets, as divided by PDGFRA amplification 
status, with PDGFRA-amplified patients (red) having significantly reduced overall survival. B. No difference was seen in survival in 
pediatric HGG patients by PDGFRA mutational status. PDGFRA amplification was associated with worse prognosis in non-brainstem 
HGG C. but not brainstem HGG (DIPG) D.
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Figure 3: Clinical detail for infant with thalamic pediatric HGG (UMPED05). A. FLAIR-imaging of left thalamic tumor in 
two year old patient at diagnosis. B. Tumorhistology (Hematoxilin and Eosin) shows hypercellular glial (GFAP-positive) tumor with diffuse 
PDGFRA-positivity and elevated proliferation index (Ki67).
Figure 4: Integrative clinical sequencing results of paired tumor and primary cell culture from UMPED05. A. Molecular 
profiling shows focal gene amplifications on chromosomes 1-8, including chromosome 4 (PDGFRA, CHIC2, RBPJ and FGF2), and (not 
shown) chromosome 8 (MYC and PVT1) and 12 (ING4, and ZNF384); and B. increased expression of FGF2 and PDGFRA, as seen in a plot 
of tumor transcriptome (RNA) sequencing data. C-D. Molecular profiling of the cells in culture at passage 15 demonstrates retention of the 
key somatic events seen in the original human tumor, including amplification and outlier expression of PDGFRA and FGF2.
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profiling (exome and transcriptome sequencing) of 
the cells in culture at passage 15, and found them to 
continue to display the key somatic events seen in the 
original human tumor, including amplification and 
outlier expression of PDGFRA and FGF2 (among others) 
(Figure 4C–4D). The only genetic differences that we 
could establish in the cultured cells were sub-clonal gains 
of point mutations in MLL3 (~10%), which are of unclear 
significance (Supplementary Figure S2).
After three passages, UMPED05 cells were treated 
with clinically-available tyrosine kinase inhibitors 
known to target PDGFR signaling, including imatinib 
(Novartis), nilotinib (Novartis), and dasatinib (Bristol-
Myers Squibb). Of the tyrosine kinase inhibitors used, 
dasatinib inhibited proliferation most effectively, with 
the lowest IC50 (Figure 5A). Our cell proliferation assay 
correlated with cell counting assessment of viability 
for all agents (data not shown). We additionally treated 
UMPED05 cells with CCNU and temozolomide, 
which are used clinically in pediatric HGG patients. 
Temozolomide showed no significant potency (IC50 = 
~1 mM), while CCNU showed moderate potency (IC50 
=100 uM) (Figure 5A). Suberanilohydroxamic acid 
(SAHA) is a histone deacetylase (HDAC) inhibitor 
which has been studied in recent clinical trials of 
pediatric and adult high-grade glioma patients [9, 10]. 
Treatment of UMPED05 with SAHA showed moderate 
potency, with an IC50 of 10 μM (Figure 5A). In order 
to determine whether reduction in proliferation was 
specific to reduction in PDGFRA expression and/or 
FGF2 expression (UMPED05 harbors amplifications 
in both), we performed in vitro targeting of UMPED05 
cells with multiple siRNAs. Reduction in proliferation 
was observed in transfection with one siPDGFRA, but 
not with two siFGF2s (Supplementary Figure S3).
Finally, we explored whether the treatment with 
dasatinib was specific to UMPED05. We selected another 
established adherent (non-growth factor supplemented) 
pediatric GBM cell culture (KNS42) which has been 
sequenced and found to have no growth factor receptor 
amplifications (COSMIC ID 907282) [11]. KNS42 was 
less sensitive to dasatinib, with a ~400 fold higher IC50 
than UMPED05 (Figure 5B). We were unable to acquire 
additional HGG cell cultures with PDGFRA alterations, 
which limited our ability to confirm that the potency 
of dasatinib was generalizable to all glioma cells with 
PDGFRA up-regulation.
DISCUSSION
Previous large scale genomic characterizations of 
pediatric HGG have shown that PDGFRA is a frequent 
tumor driver [2, 3]. However, the prognostic and treatment 
implications of PDGFRA alteration in pediatric HGG 
have not been fully characterized. By integrating genomic 
data from multiple datasets, we were able to and generate 
the largest pediatric HGG genomic dataset to date, with 
standardized somatic event calling and an adequate sample 
size for sub-group analysis.
In our dataset, the number of total number of 
pediatric patients with PDGFRA amplification or mutation 
(14.1%) was near the lower end of the range of previously 
published datasets [2, 3]. We report that PDGFRA 
mutation is prognostic in pediatric HGG. Previous large-
scale characterizations of PDGFRA alterations in glioma 
have not reported this, either because they have focused 
on adults patients [7] or amplification (by FISH) alone [8]. 
PDGFRA amplification was not prognostic by multivariate 
analysis, which may, in part, be explained by the overlap 
between amplification and location (brainstem), which is 
highly prognostic. Non-brainstem pediatric HGG with 
PDGFRA amplification carried a worse prognosis than 
non-brainstem HGG without PDGFRA amplification, by 
Kaplan-Meier analysis (P = 0.021). There were no patients 
with PDGFRA amplification with reported survival 
beyond two years in our datasets.
Since the genomic data used in our analysis does 
not include treatment data, it is possible that differences 
in outcomes among molecular sub-groups in our analyses 
may have been influenced by additional treatment factors. 
For, example, the small number of patients (n=8) with 
PDGFRA-amplified non-brainstem HGG may have 
received different therapy than the larger non-amplified 
group. Nevertheless, prognostic difference between 
PDGFRA mutation and amplification in pediatric HGG 
highlights the importance of genomic characterization at 
the DNA level for future risk-stratification, as both may 
lead to changes at the RNA and protein level.
The poor prognosis seen in all sub-groups of 
pediatric HGG, but particularly DIPG, further highlights 
the clear need to improve therapies for this patient 
population. Our method of integrative sequencing and 
co-generation of a primary cell culture at the time of 
diagnosis of a pediatric HGG offers a feasible approach 
to optimize and validate personalized molecular targets.
Dasatinib is a promising agent for pediatric HGG 
with PDGF pathway alterations (Figure 5C). Dasatinib 
is an orally bioavailable tyrosine kinase inhibitor with 
~60 fold greater inhibition of PDGFR signaling than 
earlier generation TKIs, such as imatinib [12]. While it 
was originally developed for targeting the BCR-ABL 
gene fusion, it exhibits nanomolar range activity against 
PDGFRA in leukemia [13]. In the previous pediatric Phase 
I trial using dasatinib in patients with leukemia and solid 
tumors, it was found to be well tolerated [14].
Dasatinib displays moderately favorable 
characteristics for blood-brain barrier penetration and has 
demonstrated efficacy in adult patients with CNS metastases 
of CML [15], where CSF concentrations (3 nMol/L and 20 
nMol/L) were near the IC50 we obtained for UMPED05 
(50 nMol/L) and previously published tumor cell cultures 
(4 nMol/L) [12]. Importantly, recent work has shown that 
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dasatinib (or other TKI) delivery to brain tumor parenchyma 
may be further improved by strategies to inhibit active 
efflux proteins (P-glycoprotein (P-gp) and breast cancer 
resistance protein (Bcrp1)). Recent pre-clinical strategies 
have included co-administration of TKIs with agents that 
inhibit these proteins, including mammalian target of 
rapamycin (mTOR) inhibitors [16], or elacridar [17].
When used as a single agent in recurrent adult GBM, 
dasatinib did not show efficacy [18]. This failure in adult 
patients may in part be related to the increased frequency 
of multiple tumor driving mutations in adult HGG [19]. 
Pediatric tumors, including HGG, are frequently driven 
by fewer somatic mutations than adult tumors, and 
may therefore be more ideal candidates for molecularly 
targeted agents [20]. Additionally, optimization of future 
precision-medicine based therapies for HGG (adult or 
pediatric) may benefit from combining targeted agents for 
multiple key altered pathways.
For this patient (UMPED05), attempt for treatment 
with dasatinib was not considered until she had failed all 
Figure 5: Treatment of UMPED05 with multiple chemotherapeutic agents reveals unique sensitivity to dasatinib. 
A. Dose-response curves were generated by adding chemotherapeutic agents at doses ranging from 0.01-1000 μM. After 48 hours of 
treatment, ATP levels were measured (relative light units (RLU)) in triplicate using Cell-Titer Glo and plotted versus drug concentration. 
Cells were most sensitive to dasatinib treatment (in red). B. UMPED05 is more sensitive (lower IC50) than KNS42, a pediatric GBM cell 
line without growth factor amplifications. C. Schematic representing impact of dasatinib on PDGFRA pathway.
Oncotarget9www.impactjournals.com/oncotarget
standard therapy (surgery and multi-agent chemotherapy 
designed for infants with brain tumors). Unfortunately, the 
patient passed away shortly after the tumor progressed, 
and so we were unable to determine whether the patient’s 
tumor would have responded to dasatinib clinically. Future 
precision-medicine based clinical trials for pediatric 
patients with HGG could consider up-front therapy with 
dasatinib for tumors with PDGFRA alterations.
In summary, we describe the integration of multiple 
pediatric HGG genomic datasets which allowed us 
to highlight that PDGFRA mutation is found in older 
pediatric patients and that PDGFRA amplification is 
prognostic in non-brainstem HGG. As well, we highlight 
the characterization and targeting of a novel pediatric 
HGG primary cell culture with PDGFRA amplification. 
Our work highlights the importance of genomic 
characterization of pediatric HGG for risk stratification and 
targeted therapies. Hopefully, this will be a step further in 
providing improved outcomes for this patient population.
MATERIALS AND METHODS
Human pediatric high-grade glioma dataset 
mutation analysis
Human pediatric glioma mutation assessment was 
performed using publically-available matched tumor/
non-tumor genome sequencing datasets, all of which were 
accessed through the European Genome-phenome Archive 
(EGA), accession numbers EGAS00001000192,[3, 21] 
EGAS00001000572 [22], EGAS00001000575 [23] 
EGAS0000100072[24], and additional pediatric high-
grade glioma samples (deposited at EGAS00001001436). 
Pediatric and young adult patients were included (age <30 
years old at time of diagnosis), and both brainstem and 
non-brainstem samples were included. Somatic variants 
were called in alignments, using GATK version 2 and 
annotated for consequences with the Ensembl variant 
effect predictor, as previously described [6]. Copy number 
variations were assigned using exon level log ratios of 
sequence coverage in tumor/normal pairs for all known 
genes. Log ratios were segmented using circular binary 
segmentation in the DNA copy package in R version 3.1.3 
and contiguous copy number aberrations were assigned 
using thresholds for gains/losses and amplifications/
deletions based upon the average genome wide median 
absolute deviation in each dataset. Survival analysis 
was performed using Kaplan-Meier analysis (GraphPad 
Software, Inc.) Cox proportional hazards model was used 
to assess effects of somatic mutation factors, age and 
location on the overall survival. Kappa statistics were 
calculated to quantify the association between somatic 
alterations and McNemar’s test was used to test the 
association. Significance is determined if P < 0.05. All 
analyses were conducted using SAS (version 9.4, SAS 
Institute, Cary, NC).
Human tumor immunohistochemistry
Immunohistochemistry was performed in formalin-
fixed, paraffin embedded tissue, 5 um sections, using 
antibodies against GFAP (1:3200, Dako Corporation), 
PDGFRA (1:100, Santa Cruz) and Ki67 (Clone 30-9 pre-
diluted, Ventana Medical Systems).
Molecular profiling human tumor tissue
Consent was obtained from the family to 
molecularly characterize the tumor (UMPED05) through 
the PEDS-MIONCOSEQ Integrative Sequencing Study, 
as well as to create a primary cell culture for further in 
vitro characterization and testing. Paired whole exome 
tumor DNA, cultured tumor cell DNA (passage 15), 
and germline DNA; and tumor and cultured tumor 
transcriptome sequencing was performed. In brief, 
nucleic acid preparation and high-throughput sequencing 
were performed using standard protocols in our Clinical 
Laboratory Improvement Amendments (CLIA) compliant 
sequencing lab. Paired-end whole exome libraries from 
tumor and matched normal DNAs captured by SureSelect 
Human All Exon V4 (Agilent, Santa Clara, CA), and 
transcriptome libraries from either poly-adenylated tumor 
RNA (PolyA+ transcriptome), or from total RNA captured 
by human all exon probes (capture transcriptome; Agilent, 
Santa Clara, CA) were prepared and sequenced using the 
Illumina HiSeq 2500 (Illumina Inc, San Diego, CA). 
Aligned exome and transcriptome sequencing reads were 
analyzed to detect putative somatic mutations, insertions/
deletions (indels), copy-number alterations, gene fusions, 
and gene expression as described previously [25, 26].
Cell culture
Human tumor primary cell culture UMPED05 was 
generated by harvesting tumor cells at the time of tumor 
resection by members of the University of Michigan 
Neuro-Oncology Translational Laboratory. The tumor 
tissue was transferred on ice and immediately dissociated 
using non-enzymatic cell dissociation buffer (Gibco, 
13151-014), filtered and maintained in adherent cell line 
media [DMEM/F12 with L-Glutamine (Gibco, 11320-
033)], 10% Fetal Bovine Serum (Gibco, 10437-077), 
Antibiotic-Antimycotic (Gibco 15240-062), and Normocin 
(Invivogen).
The pediatric GBM cell culture KNS42 [27] was 
generously provided by Dr. Alan Meeker at Johns Hopkins 
University, and maintained in above conditions to grow 
adherently.
Treatment of cells with chemotherapy and 
siRNA
For high-grade glioma primary cell cultures 
treatment assays, cells were passaged and plated in a 96-
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well plate at 2,000 cells/well in triplicate per condition. 
At 24 hours, cells were treated with chemotherapeutic 
agents, siRNA, or control, and assessed for viability 72 
hours later using the Cell Titer Glo Assay (Promega) [28]. 
ON-TARGET PLUS siRNAs (GE Healthcare Dharmacon) 
against PDGFRA (J003162-11; J003162-12) and FGF2 
(J006695-05; J006695-06) were used according to 
manufacturer’s protocol. Chemotherapy was administered 
at a range of concentrations (0.01-1000 μM) based on 
previously published data: temozolomide (Sigma), CCNU 
(Sigma), Suberanilohydroxamic acid (SAHA), imatinib 
(Novartis), nilotinib (Novartis), and dasatinib (Bristol-
Myers Squibb). Dose response curves were plotted using 
GraphPad Software, and IC50 was calculated as the dose 
at which there was a 50% reduction in cell proliferation 
form untreated cells.
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